## **UNITEDHEALTH GROUP®**

### UnitedHealth Group Reports First Quarter 2022 Results

- Revenues of \$80.1 Billion Grew \$10 Billion or 14% Year-Over-Year, with Double-Digit Growth at both Optum and UnitedHealthcare
- Earnings from Operations were \$7 Billion
- Cash Flows from Operations were \$5.3 Billion
- Earnings were \$5.27 Per Share, Adjusted Earnings \$5.49 Per Share

**MINNETONKA, Minn. (April 14, 2022)** – Strong and well-balanced growth continued across UnitedHealth Group (NYSE: UNH) in the first quarter of 2022.

"Disciplined execution of our long-term strategy, with a sharp focus on ensuring access to care for the people we serve, enabled us to deliver high-quality, diversified growth across Optum and UnitedHealthcare during this first quarter of 2022," said Andrew Witty, chief executive officer of UnitedHealth Group.

Based upon the first quarter performance and enterprise-wide growth outlook, the Company increased its full year net earnings outlook to \$20.30 to \$20.80 per share and adjusted net earnings to \$21.20 to \$21.70 per share.

## **UNITEDHEALTH GROUP®**

Quarterly Financial Performance <u>Three Months Ended</u>						
	March 31, March 31, December 31, <u>2022</u> <u>2021</u> <u>2021</u>					
Revenues Earnings from Operations Net Margin	\$80.1 billion \$ 7.0 billion 6.3%	\$70.2 billion \$ 6.7 billion 6.9%	\$73.7 billion \$ 5.5 billion 5.5%			

- UnitedHealth Group's first quarter 2022 revenues grew \$10 billion or 14.2% to \$80.1 billion year-over-year, including diversified, double-digit growth at both Optum and UnitedHealthcare.
- First quarter 2022 earnings from operations were \$7 billion and adjusted net earnings were \$5.49 per share. Year-over-year earnings growth was led by Optum Health, due to its positive impact for patients and the accelerating expansion of its value-based care delivery initiatives.
- The first quarter 2022 medical care ratio was 82% compared to 80.9% last year, due to COVID effects and business mix. Favorable medical reserve development of \$290 million compared to \$1 billion in the year ago first quarter. Days claims payable were 49.1, compared to 46.8 in the fourth quarter 2021 and 49.8 in the first quarter 2021.
- The first quarter 2022 operating cost ratio of 14.2% decreased from 14.6% in 2021 due to COVID effects and continued productivity advances, partially offset by business mix and the investments the Company continues to make to accelerate and support future growth opportunities.
- Cash flows from operations for the first quarter 2022 were \$5.3 billion or 1-times net income. The Company returned \$3.9 billion to shareholders in the first quarter through dividends and share repurchases. Return on equity of 27.8% in the quarter reflected the Company's consistent and diverse earnings profile and efficient capital structure.

# UnitedHealthcare<sup>®</sup>

UnitedHealthcare provides health care benefits globally, serving individuals and employers, and Medicare and Medicaid beneficiaries. UnitedHealthcare is dedicated to improving the value customers and consumers receive by improving health and wellness, enhancing the quality of care received, simplifying the health care experience and reducing the total cost of care.

Quarterly Financial Performance <u>Three Months Ended</u>						
	March 31, March 31, December 31, <u>2022</u> <u>2021</u> <u>2021</u>					
Revenues Earnings from Operations Operating Margin	\$62.6 billion \$ 3.8 billion 6.1%	\$55.1 billion \$ 4.1 billion 7.5%	\$56.4 billion \$ 2.1 billion 3.8%			

- UnitedHealthcare first quarter revenues of \$62.6 billion grew \$7.5 billion or 13.6% year-overyear reflecting broad-based growth.
- In the first quarter of 2022, UnitedHealthcare grew to serve 1.5 million more people than a year ago, led by continued strong growth in Medicare Advantage and Dual Special Needs Plans and in the broader Medicaid market. UnitedHealthcare's expanding portfolio of innovative, new offerings for people served by commercial benefits, including physician-led, consumer-tailored and virtual-first products, grew by 350,000 people over the past year.
- First quarter 2022 operating earnings were \$3.8 billion compared to \$4.1 billion last year, reflecting strong growth in people served and revenue, and continued effective medical and operating cost management. The year ago result reflects the effects of pandemic-disrupted care patterns.

# Optum

Optum's health services businesses serve the global health care marketplace, including payers, care providers, employers, governments, life sciences companies and consumers. Using market-leading information, analytics, technology and clinical insights, Optum helps improve overall health system performance: optimizing care quality, reducing care costs and improving the consumer experience.

Quarterly Financial Performance <u>Three Months Ended</u>						
	March 31, March 31, December 31, <u>2022</u> <u>2021</u> <u>2021</u>					
Revenues Earnings from Operations Operating Margin	\$43.3 billion \$ 3.2 billion 7.3%	\$36.4 billion \$ 2.6 billion 7.2%	\$41.1 billion \$ 3.4 billion 8.3%			

- Optum first quarter revenues grew 18.9% to \$43.3 billion and operating earnings grew 19.8% to \$3.2 billion.
- Optum Health revenue per consumer served increased 33% over the year ago quarter, driven by growth of people served under value-based care arrangements. Optum Health now expects to serve 600,000 new patients under such arrangements in 2022 compared to its initial outlook of 500,000. The results reflect the continued expansion of care services offered, with at-home and digital offerings complementing and integrating with growing clinic-based and outpatient services, including ambulatory surgical care.
- Optum Insight's revenue backlog increased by \$2 billion to \$22.8 billion compared to a year ago, driven by strong growth and execution in its expanding comprehensive managed services offerings for health systems. The breadth of services offered by Optum Insight continues to advance in areas such as payment integrity, digital modernization and care coordination.
- Optum Rx's robust revenue growth of 11% in the first quarter reflects continued advancements in serving new, large health plan clients and further expansion of community-behavioral, specialty pharmacy and e-commerce services. Adjusted scripts grew to 352 million compared to 329 million last year.

#### About UnitedHealth Group

UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at <u>www.unitedhealthgroup.com</u> and follow <u>@UnitedHealthGrp</u> on Twitter.

#### Earnings Conference Call

As previously announced, UnitedHealth Group will discuss the company's results, strategy and future outlook on a conference call with investors at 8:45 a.m. Eastern Time today. UnitedHealth Group will host a live webcast of this conference call from the Investor Relations page of the company's website (<u>www.unitedhealthgroup.com</u>). Following the call, a webcast replay will be available on the same site through April 28, 2022. The conference call replay can also be accessed by dialing 1-888-203-1112, Conference Code: 3063505. This earnings release and the Form 8-K dated April 14, 2022, can also be accessed from the Investor Relations page of the Company's website.

#### **Non-GAAP Financial Information**

This news release presents non-GAAP financial information provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America ("GAAP"). A reconciliation of the non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.

#### Forward-Looking Statements

The statements, estimates, projections, guidance or outlook contained in this document include "forward-looking" statements which are intended to take advantage of the "safe harbor" provisions of the federal securities law. The words "believe," "expect," "intend," "estimate," "anticipate," "forecast," "outlook," "plan," "project," "should" and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: risks associated with public health crises, large-scale medical emergencies and pandemics, such as the COVID-19 pandemic; our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; the DOJ's legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting

Page 5 of 6

revenue; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; failure to protect proprietary rights to our databases, software and related products; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to develop and deliver innovative products to health care payers and expand access to virtual care; changes in or challenges to our public sector contract awards; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; failure to attract, develop, retain, and manage the succession of key employees and executives; the impact of potential changes in tax laws and regulations (including any increase in the U.S. income tax rate applicable to corporations); failure to achieve targeted operating cost productivity improvements; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to manage successfully our strategic alliances or complete or receive anticipated benefits of strategic transactions; fluctuations in foreign currency exchange rates; downgrades in our credit ratings; our investment portfolio performance; impairment of our goodwill and intangible assets; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.

###

Investor Contact: Zack Sopcak

Senior Vice President 952-936-7215 zack.sopcak@uhg.com

Media Contact: Matt Stearns Senior Vice President 202-276-0085 matt.stearns@uhg.com

### UNITEDHEALTH GROUP Earnings Release Schedules and Supplementary Information Quarter Ended March 31, 2022

- Condensed Consolidated Statements of Operations
- Condensed Consolidated Balance Sheets
- Condensed Consolidated Statements of Cash Flows
- Supplemental Financial Information Businesses
- Supplemental Financial Information Business Metrics
- Reconciliation of Non-GAAP Financial Measure

#### UNITEDHEALTH GROUP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

#### (in millions, except per share data) (unaudited)

	Three Months Ended March 31,	
-	2022	2021
Revenues		
Premiums	\$64,070	\$55,486
Products	9,340	8,340
Services	6,372	5,918
Investment and other income	367	452
- Total revenues	80,149	70,196
Operating costs		
Medical costs	52,523	44,904
Operating costs	11,401	10,223
Cost of products sold	8,487	7,572
Depreciation and amortization	788	758
- Total operating costs	73,199	63,457
Earnings from operations	6,950	6,739
Interest expense	(433)	(397)
Earnings before income taxes	6,517	6,342
Provision for income taxes	(1,369)	(1,364)
Net earnings	5,148	4,978
Earnings attributable to noncontrolling interests	(121)	(116)
Net earnings attributable to UnitedHealth Group common shareholders	\$5,027	\$4,862
Diluted earnings per share attributable to UnitedHealth Group common shareholders	\$5.27	\$5.08
Adjusted earnings per share attributable to UnitedHealth Group common shareholders (a)	\$5.49	\$5.31
= Diluted weighted-average common shares outstanding	954	957

(a) See page 6 for a reconciliation of the non-GAAP measure

#### UNITEDHEALTH GROUP CONDENSED CONSOLIDATED BALANCE SHEETS (in millions) (unaudited)

	March 31, 2022	December 31, 2021
Assets		
Cash and short-term investments	\$28,396	\$23,907
Accounts receivable, net	18,871	14,216
Other current assets	21,762	23,635
Total current assets	69,029	61,758
Long-term investments	42,353	43,114
Other long-term assets	109,856	107,334
Total assets	\$221,238	\$212,206
Liabilities, redeemable noncontrolling interests and equity		
Medical costs payable	\$28,676	\$24,483
Short-term borrowings and current maturities of long-term debt	6,697	3,620
Other current liabilities		50,189
Total current liabilities	88,170	78,292
Long-term debt, less current maturities	40,796	42,383
Other long-term liabilities	14,625	15,052
Redeemable noncontrolling interests	1,519	1,434
Equity	76,128	75,045
Total liabilities, redeemable noncontrolling interests and equity	\$221,238	\$212,206

#### UNITEDHEALTH GROUP CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions)

(unaudited)

Net earnings\$5,148\$4,97Noncash items:Depreciation and amortization78875Deferred income taxes and other17826Share-based compensation27925Net changes in operating assets and liabilities(1,094)(27Cash flows from operating assets and maturities(1,094)(27Cash flows from operating activities5,3196,00Investing Activities(1,632)(1,71-Purchases of property, equipment and capitalized software(555)(566)Cash flows used for investing activities(1,231)(1,19)Other, net(255)(23)Cash flows used for investing activities(3,673)(3,70)Financing Activities(1,363)(1,18)Common share repurchases(2,500)(1,652)Dividends paid(1,363)(1,18)Net change in short-term borrowings and long-term debt2,0482,90Other, net4,11971Cash flows from financing activities2,30476Effect of exchange rate changes on cash and cash equivalents4,1073,00Cash and cash equivalents4,1073,00Cash and cash equivalents, beginning of period21,37516,92			Three Months Ended March 31,	
Net earnings\$5,148\$4,97Noncash items:Depreciation and amortization78875Defered income taxes and other17826Share-based compensation27925Net changes in operating assets and liabilities(1,094)(27)Cash flows from operating assets and maturities(1,094)(27)Cash flows from operating activities5,3196,00Investing Activities(1,632)(1,71)Purchases of property, equipment and capitalized software(555)(560)Cash flows used for investing activities(1,231)(1,19)Other, net(255)(23)(23)Cash flows used for investing activities(3,673)(3,70)Financing Activities(2,500)(1,653)(1,652)Dividends paid(1,363)(1,18)(1,18)Net change in short-term borrowings and long-term debt2,0482,90Other, net4,11971(2,304)Cash flows from financing activities2,30476Effect of exchange rate changes on cash and cash equivalents157(5Cash and cash equivalents4,1073,00Cash and cash equivalents, beginning of period21,37516,92		2022	2021	
Noncash items:       788       75         Depreciation and amortization       788       75         Deferred income taxes and other       178       22         Share-based compensation       299       25         Net changes in operating assets and liabilities       (1,094)       (27)         Cash flows from operating activities       (1,632)       (1,71+         Investing Activities       (1,632)       (1,71+         Purchases of property, equipment and capitalized software       (555)       (556)         Cash flows used for investing activities       (1,231)       (1,19)         Other, net       (255)       (23)         Cash flows used for investing activities       (3,673)       (3,70)         Financing Activities       (1,363)       (1,18)         Common share repurchases       (2,500)       (1,655)         Dividends paid       (1,363)       (1,18)         Net change in short-term borrowings and long-term debt       2,048       2,90         Other, net       4,119       71         Cash flows from financing activities       157       (5         Cash flows from financing activities       2,044       2,904         Other, net       4,119       71         Cash flows	Operating Activities			
Depreciation and amortization78875Deferred income taxes and other17826Share-based compensation29925Net changes in operating assets and liabilities(1,094)(27)Cash flows from operating activities5,3196,00Investing Activities(1,632)(1,71)Purchases of investments, net of sales and maturities(1,632)(1,71)Purchases of property, equipment and capitalized software(555)(56)Cash flows used for investing activities(1,231)(1,19)Other, net(255)(23)Cash flows used for investing activities(3,673)(3,70)Financing Activities(1,363)(1,18)Dividends paid(1,363)(1,18)Net change in short-term borrowings and long-term debt2,0482,904Other, net2,30476Cash flows from financing activities2,30476Effect of exchange rate changes on cash and cash equivalents157(5Cash and cash equivalents4,1073,00Cash and cash equivalents21,37516,92	Net earnings	\$5,148	\$4,978	
Deferred income taxes and other17828Share-based compensation29925Net changes in operating assets and liabilities(1,094)(27)Cash flows from operating activities5,3196,00Investing Activities(1,632)(1,71)Purchases of investments, net of sales and maturities(1,632)(1,71)Purchases of property, equipment and capitalized software(555)(56)Cash flows used for investing activities(1,231)(1,131)Other, net(255)(23)Cash flows used for investing activities(3,673)(3,70)Financing Activities(1,363)(1,18)Common share repurchases(1,363)(1,18)Dividends paid(1,363)(1,18)Net change in short-term borrowings and long-term debt2,0482,900Other, net4,11974Cash flows from financing activities157(5Effect of exchange rate changes on cash and cash equivalents4,1073,000Cash and cash equivalents<	Noncash items:			
Share-based compensation29925Net changes in operating assets and liabilities(1,094)(27)Cash flows from operating activities5,3196,00Investing Activities(1,632)(1,71-Purchases of investments, net of sales and maturities(1,632)(1,71-Purchases of property, equipment and capitalized software(555)(566)Cash paid for acquisitions, net(1,231)(1,19)Other, net(255)(23)Cash flows used for investing activities(3,673)(3,70)Financing Activities(2,500)(1,650)Common share repurchases(2,500)(1,650)Dividends paid(1,363)(1,18)Net change in short-term borrowings and long-term debt2,0482,904Cash flows from financing activities2,30478Effect of exchange rate changes on cash and cash equivalents157(5Cash and cash equivalents, beginning of period21,37516,92	Depreciation and amortization	788	758	
Net changes in operating assets and liabilities(1,094)(27Cash flows from operating activities5,3196,00Investing Activities(1,632)(1,71-Purchases of investments, net of sales and maturities(1,632)(1,71-Purchases of property, equipment and capitalized software(555)(566)Cash paid for acquisitions, net(1,231)(1,19:Other, net(255)(23:Cash flows used for investing activities(3,673)(3,70)Financing Activities(2,500)(1,656)Dividends paid(1,363)(1,18)Net change in short-term borrowings and long-term debt2,0482,900Other, net4,11977Cash flows from financing activities2,304775Effect of exchange rate changes on cash and cash equivalents157(5Cash and cash equivalents4,1073,002Cash and cash equivalents4,1073,002Cash and cash equivalents4,1073,002Cash and cash equivalents21,37516,922	Deferred income taxes and other		286	
Cash flows from operating activities5,3196,00Investing Activities(1,632)(1,714Purchases of investments, net of sales and maturities(1,632)(1,714Purchases of property, equipment and capitalized software(555)(566Cash paid for acquisitions, net(1,231)(1,193Other, net(255)(233Cash flows used for investing activities(3,673)(3,707Financing Activities(2,500)(1,650Dividends paid(1,363)(1,188)Net change in short-term borrowings and long-term debt2,0482,904Other, net4,11974Cash flows from financing activities2,30476Effect of exchange rate changes on cash and cash equivalents157(5Increase in cash and cash equivalents4,1073,03Cash and cash equivalents21,37516,92	Share-based compensation		256	
Investing Activities       (1,632)       (1,714)         Purchases of investments, net of sales and maturities       (1,632)       (1,714)         Purchases of property, equipment and capitalized software       (555)       (566)         Cash paid for acquisitions, net       (1,231)       (1,193)         Other, net       (255)       (233)         Cash flows used for investing activities       (3,673)       (3,70)         Financing Activities       (2,500)       (1,656)         Common share repurchases       (2,500)       (1,656)         Dividends paid       (1,363)       (1,18)         Net change in short-term borrowings and long-term debt       2,048       2,900         Other, net       2,304       76         Cash flows from financing activities       2,304       76         Effect of exchange rate changes on cash and cash equivalents       157       (5         Increase in cash and cash equivalents       4,107       3,03         Cash and cash equivalents, beginning of period       21,375       16,92	Net changes in operating assets and liabilities	(1,094)	(273)	
Investing ActivitiesPurchases of investments, net of sales and maturities(1,632)(1,714)Purchases of property, equipment and capitalized software(555)(566)Cash paid for acquisitions, net(1,231)(1,193)Other, net(255)(233)Cash flows used for investing activities(3,673)(3,700)Financing Activities(2,500)(1,650)Common share repurchases(2,500)(1,650)Dividends paid(1,363)(1,180)Net change in short-term borrowings and long-term debt2,0482,900Other, net4,119740Cash flows from financing activities1567(550)Effect of exchange rate changes on cash and cash equivalents1567(550)Increase in cash and cash equivalents4,1073,003Cash and cash equivalents21,37516,922	Cash flows from operating activities	5,319	6,005	
Purchases of property, equipment and capitalized software(555)(566)Cash paid for acquisitions, net(1,231)(1,192)Other, net(255)(232)Cash flows used for investing activities(3,673)(3,700)Financing Activities(2,500)(1,650)Common share repurchases(2,500)(1,650)Dividends paid(1,363)(1,18)Net change in short-term borrowings and long-term debt2,0482,900Other, net4,11971Cash flows from financing activities2,30476Effect of exchange rate changes on cash and cash equivalents157(5Increase in cash and cash equivalents4,1073,03Cash and cash equivalents, beginning of period21,37516,92	Investing Activities			
Cash paid for acquisitions, net(1,231)(1,193)Other, net(255)(233)Cash flows used for investing activities(3,673)(3,70)Financing Activities(2,500)(1,650)Common share repurchases(1,363)(1,18)Dividends paid(1,363)(1,18)Net change in short-term borrowings and long-term debt2,0482,900Other, net4,11971Cash flows from financing activities2,30478Effect of exchange rate changes on cash and cash equivalents157(5)Increase in cash and cash equivalents4,1073,03Cash and cash equivalents, beginning of period21,37516,92	Purchases of investments, net of sales and maturities		(1,714)	
Other, net(255)(233)Cash flows used for investing activities(3,673)(3,70)Financing Activities(3,673)(3,70)Common share repurchases(2,500)(1,650)Dividends paid(1,363)(1,18)Net change in short-term borrowings and long-term debt2,0482,900Other, net4,11971Cash flows from financing activities2,30478Effect of exchange rate changes on cash and cash equivalents157(5)Increase in cash and cash equivalents4,1073,03Cash nd cash equivalents, beginning of period21,37516,92	Purchases of property, equipment and capitalized software		(568)	
Cash flows used for investing activities(3,673)(3,70)Financing Activities(2,500)(1,650)Common share repurchases(1,363)(1,18)Dividends paid(1,363)(1,18)Net change in short-term borrowings and long-term debt2,0482,900Other, net4,11971Cash flows from financing activities2,30478Effect of exchange rate changes on cash and cash equivalents157(5)Increase in cash and cash equivalents4,1073,03Cash and cash equivalents, beginning of period21,37516,92	Cash paid for acquisitions, net		(1,193)	
Financing Activities       (2,500)       (1,650)         Common share repurchases       (1,363)       (1,180)         Dividends paid       (1,363)       (1,180)         Net change in short-term borrowings and long-term debt       2,048       2,900         Other, net       4,119       710         Cash flows from financing activities       2,304       780         Effect of exchange rate changes on cash and cash equivalents       157       (5)         Increase in cash and cash equivalents       4,107       3,03         Cash and cash equivalents, beginning of period       21,375       16,92	Other, net		(232)	
Common share repurchases(2,500)(1,650)Dividends paid(1,363)(1,180)Net change in short-term borrowings and long-term debt2,0482,900Other, net4,119710Cash flows from financing activities2,304780Effect of exchange rate changes on cash and cash equivalents157(500)Increase in cash and cash equivalents4,1073,030Cash and cash equivalents, beginning of period21,37516,920	Cash flows used for investing activities	(3,673)	(3,707)	
Dividends paid(1,363)(1,18)Net change in short-term borrowings and long-term debt2,0482,90Other, net4,11971Cash flows from financing activities2,30478Effect of exchange rate changes on cash and cash equivalents157(5)Increase in cash and cash equivalents4,1073,03Cash and cash equivalents, beginning of period21,37516,92	Financing Activities			
Net change in short-term borrowings and long-term debt2,0482,90Other, net4,11971Cash flows from financing activities2,30478Effect of exchange rate changes on cash and cash equivalents157(5)Increase in cash and cash equivalents4,1073,03Cash and cash equivalents, beginning of period21,37516,92	Common share repurchases	(2,500)	(1,650)	
Other, net4,11971Cash flows from financing activities2,30478Effect of exchange rate changes on cash and cash equivalents157(5)Increase in cash and cash equivalents4,1073,03Cash and cash equivalents, beginning of period21,37516,92	Dividends paid		(1,181)	
Cash flows from financing activities2,30478Effect of exchange rate changes on cash and cash equivalents157(5Increase in cash and cash equivalents4,1073,03Cash and cash equivalents, beginning of period21,37516,92	Net change in short-term borrowings and long-term debt	2,048	2,907	
Effect of exchange rate changes on cash and cash equivalents       157       (5)         Increase in cash and cash equivalents       4,107       3,03         Cash and cash equivalents, beginning of period       21,375       16,92	Other, net	4,119	711	
Increase in cash and cash equivalents 4,107 3,03 Cash and cash equivalents, beginning of period 21,375 16,92	Cash flows from financing activities	2,304	787	
Cash and cash equivalents, beginning of period 21,375 16,92	Effect of exchange rate changes on cash and cash equivalents	157	(51)	
	Increase in cash and cash equivalents	4,107	3,034	
Cash and cash equivalents, end of period \$25,482 \$19,95	Cash and cash equivalents, beginning of period	21,375	16,921	
	Cash and cash equivalents, end of period	\$25,482	\$19,955	

#### UNITEDHEALTH GROUP **SUPPLEMENTAL FINANCIAL INFORMATION - BUSINESSES**

#### (in millions, except percentages) (unaudited)

	Three Months Ended March 31,	
	2022	2021
Revenues		
UnitedHealthcare	\$62,595	\$55,114
Optum	43,259	36,384
Eliminations	(25,705)	(21,302)
Total consolidated revenues	\$80,149	\$70,196
Earnings from Operations		
UnitedHealthcare	\$3,798	\$4,108
Optum (a)		2,631
Total consolidated earnings from operations	\$6,950	\$6,739
Operating Margin		
UnitedHealthcare		7.5%
Optum		7.2%
Consolidated operating margin		9.6%
Revenues		
UnitedHealthcare Employer & Individual - Domestic	\$15,822	\$14,632
UnitedHealthcare Employer & Individual - Global		2,035
UnitedHealthcare Employer & Individual - Total	17,955	16,667
UnitedHealthcare Medicare & Retirement		25,474
UnitedHealthcare Community & State		12,973
Optum Health	\$16,682	\$12,403
Optum Insight		2,852
Optum Rx	23,911	21,604
Optum eliminations		(475)

Earnings from operations for Optum for the three months ended March 31, 2022 and 2021 included \$1,366 and \$962 for Optum Health; \$847 and \$779 for Optum (a) Insight; and \$939 and \$890 for Optum Rx, respectively.

#### UNITEDHEALTH GROUP SUPPLEMENTAL FINANCIAL INFORMATION - BUSINESS METRICS

#### UNITEDHEALTHCARE CUSTOMER PROFILE

(in thousands)

People Served	March 31, 2022	December 31, 2021	March 31, 2021
Commercial - Domestic:			
Risk-based	7,950	7,985	7,860
Fee-based	18,460	18,595	18,455
 Total Commercial - Domestic	26,410	26,580	26,315
Medicare Advantage	6,890	6,490	6,335
Medicaid	7,810	7,655	6,975
Medicare Supplement (Standardized)	4,355	4,395	4,390
 Total Community and Senior	19,055	18,540	17,700
Total UnitedHealthcare - Domestic Medical	45,465	45,120	44,015
Commercial - Global	5,500	5,510	5,460
 Total UnitedHealthcare - Medical =	50,965	50,630	49,475
Supplemental Data			
Medicare Part D stand-alone	3,360	3,700	3,795

#### **OPTUM PERFORMANCE METRICS**

	March 31, 2022	December 31, 2021	March 31, 2021
Optum Health Consumers Served (in millions)	100	100	99
Optum Insight Contract Backlog (in billions)	\$22.8	\$22.4	\$20.8
Optum Rx Quarterly Adjusted Scripts (in millions)	352	353	329

Note: UnitedHealth Group served 148 million unique individuals across all businesses at March 31, 2022.

#### UNITEDHEALTH GROUP RECONCILIATION OF NON-GAAP FINANCIAL MEASURE (in millions, except per share data)

(unaudited)

#### ADJUSTED NET EARNINGS PER SHARE<sup>(a)</sup>

	Three Months Ended March 31,		Projected Year Ended December 31,	
	2022	2021	2022	
GAAP net earnings attributable to UnitedHealth Group common shareholders	\$5,027	\$4,862	\$19,250 - \$19,825	
Intangible amortization	281	294	~1,130	
Tax effect of intangible amortization	(69)	(71)	~(280)	
Adjusted net earnings attributable to UnitedHealth Group common shareholders	\$5,239	\$5,085	\$20,100 - \$20,675	
GAAP diluted earnings per share	\$5.27	\$5.08	\$20.30 - \$20.80	
Intangible amortization per share	0.29	0.31	~1.20	
Tax effect per share of intangible amortization	(0.07)	(0.08)	~(0.30)	
Adjusted diluted earnings per share	\$5.49	\$5.31	\$21.20 - \$21.70	

(a) Adjusted net earnings per share is a non-GAAP financial measure. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP.

Adjusted net earnings per share excludes from the relevant GAAP metric, as applicable, intangible amortization and other items, if any, that do not relate to the Company's underlying business performance. Management believes that the use of adjusted net earnings per share provides investors and management useful information about the earnings impact of acquisition-related intangible asset amortization. As amortization fluctuates based on the size and timing of the Company's acquisition activity, management believes this exclusion provides a more useful comparison of the Company's underlying business performance and trends from period to period. While intangible assets contribute to the Company's revenue generation, the intangible amortization is not directly related. Therefore, the related revenues are included in adjusted earnings per share.